Treating young patients with breast cancer. The evidence suggests that all should be treated with adjuvant therapy.
作者信息
Dixon J M, Hortobagyi G
出版信息
BMJ. 2000 Feb 19;320(7233):457-8. doi: 10.1136/bmj.320.7233.457.
Abstract
摘要
相似文献
1
Treating young patients with breast cancer. The evidence suggests that all should be treated with adjuvant therapy.
BMJ. 2000 Feb 19;320(7233):457-8. doi: 10.1136/bmj.320.7233.457.
2
Early breast cancer: adjuvant chemotherapy or radiotherapy, or both?
Acta Oncol. 2006;45(5):514-6. doi: 10.1080/02841860600839241.
3
4
[Local recurrence in premenopausal women with breast cancer: risk factors and effect of therapy].
Strahlenther Onkol. 2001 Jan;177(1):52-3.
5
Benefit/risk for adjuvant breast cancer therapy with tamoxifen or aromatase inhibitor use by age, and race/ethnicity.
Breast Cancer Res Treat. 2015 Dec;154(3):609-16. doi: 10.1007/s10549-015-3647-1. Epub 2015 Nov 24.
6
Long-term outcome after postmastectomy radiation therapy for breast cancer patients at high risk for local-regional recurrence.
Cancer J Sci Am. 1999 Mar-Apr;5(2):77-83.
7
Adjuvant chemotherapy in early breast cancer.
Dan Med J. 2016 May;63(5).
8
Adjuvant treatment in high-risk breast cancer.
Br J Hosp Med. 1996;55(4):156-8.
9
Impact of oncotype DX recurrence score in the management of breast cancer cases.
Clin Breast Cancer. 2014 Jun;14(3):182-90. doi: 10.1016/j.clbc.2013.12.002. Epub 2013 Dec 27.
10
Adjuvant tamoxifen-induced mammographic breast density reduction as a predictor for recurrence in estrogen receptor-positive premenopausal breast cancer patients.
Breast Cancer Res Treat. 2013 Dec;142(3):559-67. doi: 10.1007/s10549-013-2726-4.
引用本文的文献
1
A risk score based on histopathological features predicts higher risk of distant recurrence in premenopausal patients with lymph node-negative endocrine-responsive breast cancer.
Breast. 2012 Oct;21(5):621-8. doi: 10.1016/j.breast.2012.06.003. Epub 2012 Jun 29.
本文引用的文献
1
Factors influencing the effect of age on prognosis in breast cancer: population based study.
BMJ. 2000 Feb 19;320(7233):474-8. doi: 10.1136/bmj.320.7233.474.
2
Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study.
J Clin Oncol. 1999 Sep;17(9):2659-69. doi: 10.1200/JCO.1999.17.9.2659.
3
Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer.
J Natl Cancer Inst. 1998 Nov 4;90(21):1601-8. doi: 10.1093/jnci/90.21.1601.
4
Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
Lancet. 1998 Sep 19;352(9132):930-42.
5
Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
Lancet. 1998 May 16;351(9114):1451-67.
6
Radiotherapy and chemotherapy in high-risk breast cancer.
N Engl J Med. 1998 Jan 29;338(5):330-1; author reply 331-2.
7
Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial.
N Engl J Med. 1997 Oct 2;337(14):949-55. doi: 10.1056/NEJM199710023371401.
8
The efficacy and cost-effectiveness of adjuvant therapy of early breast cancer in premenopausal women.
J Clin Oncol. 1993 Apr;11(4):771-6. doi: 10.1200/JCO.1993.11.4.771.
9
Relationship of patient age to pathologic features of the tumor and prognosis for patients with stage I or II breast cancer.
J Clin Oncol. 1994 May;12(5):888-94. doi: 10.1200/JCO.1994.12.5.888.
10
Zotero 插件